Search

Lars Eyde Theill

from Thousand Oaks, CA
Age ~68
Get Report
Also known as:
Lars E Theill, Lars Ryde Theill, Lars E Theil
Phone and address:
1874 Calle Borrego, Thousand Oaks, CA 91360
(805) 480-0845
Related to:
Susanne Theill, 70Michelle Rasic, 53David G AddisNick Rasic, 61David Addis, 63Anthony J Rasic, 55
Connected to:
Jhonas V Theill, 66John J Theillon, 95Barbara R Theilmann, 72Jeffrey J Theim, 56Jennifer K Theim, 46Justin Theim, 84Rachel R Theim, 47Alex Theimer, 32Gerhard Theimer, 67Herbert A Theimer, 95

Lars Theill Phones & Addresses

  • 1874 Calle Borrego, Thousand Oaks, CA 91360 (805) 480-0845
  • Malibu, CA
  • Del Mar, CA
  • Panorama City, CA
  • Los Angeles, CA
  • Ventura, CA

Work

Company: Logix pharmaceuticals inc. Apr 2009 Address: Westlake Village, California Position: Partner and co-founder

Education

Degree: Doctor of Philosophy (Ph.D.) School / High School: Aarhus Universitet / Aarhus University Specialities: Biochemistry and Molecular Biology

Languages

English • Danish

Awards

Patents awarded: • "Antibody to TNF receptor-like molecules... • "Nucleic acids encoding MK61 receptors",... • "APRIL/G70, BCMA, BLYS/AGP-3 and TACI", ... • "DKR polypeptides", 2002 • "Neurogene", 1998

Industries

Biotechnology

Resumes

Resumes

Lars Theill Photo 1

Biotech Professional

View page
Position:
Partner and co-founder at Logix Pharmaceuticals Inc., Partner and co-founder at Medolution ltd
Location:
Thousand Oaks, California
Industry:
Biotechnology
Work:
Logix Pharmaceuticals Inc. - Westlake Village, California since Apr 2009
Partner and co-founder
Medolution ltd - Taizhou City, China, and Westlake Village, California since Jan 2009
Partner and co-founder
Amgen - Thousand Oaks Aug 1992 - Nov 2007
Senior Principal Scientist
UCSD - La Jolla, California Feb 1988 - Feb 1992
Postdoctoral Fellow
Education:
Aarhus Universitet / Aarhus University
Doctor of Philosophy (Ph.D.), Biochemistry and Molecular Biology
Honor & Awards:
Patents awarded: "Antibody to TNF receptor-like molecules", 2009 "Nucleic acids encoding MK61 receptors", 2004 "APRIL/G70, BCMA, BLYS/AGP-3 and TACI", 2004 "DKR polypeptides", 2002 "Neurogene", 1998
Languages:
English
Danish

Business Records

Name / Title
Company / Classification
Phones & Addresses
Lars Eyde Theill
President
LOGIX PHARMACEUTICALS, INC
Business Services at Non-Commercial Site
1874 Calle Borrego, Thousand Oaks, CA 91360
Lars E. Theill
Principal
Logix Pharmaceuticals
Drug Discovery and Development
6824 Las Olas Way, Malibu, CA 90265

Publications

Us Patents

Dkr Polypeptides

View page
US Patent:
6344541, Feb 5, 2002
Filed:
Sep 25, 1998
Appl. No.:
09/161241
Inventors:
Michael Brian Bass - Thousand Oaks CA
John Kevin Sullivan - Newbury Park CA
Lars Eyde Theill - Thousand Oaks CA
Daguang Wang - Thousand Oaks CA
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C07K 1447
US Classification:
530324, 530350
Abstract:
Disclosed are nucleic acid molecules encoding novel DKR polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

Methods And Compositions Of Matter Concerning April/G70, Bcma, Blys/Agp-3 And Taci

View page
US Patent:
6774106, Aug 10, 2004
Filed:
May 14, 2001
Appl. No.:
09/854864
Inventors:
Lars Eyde Theill - Thousand Oaks CA
Gang Yu - Thousand Oaks CA
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 3816
US Classification:
514 12, 4241851, 4241921
Abstract:
This invention concerns interactions among APRIL/G70, AGP-3/BLYS, BCMA, and TACI and related methods of use and compositions of matter. It has been found that (1) sAPRIL/G70 binds to the cell-surface receptors BCMA and TACI on T and B lymphoma cells, resulting in stimulation of proliferation of primary human and mouse B and T cells both in vitro and in vivo; (2) APRIL competes with AGP3s binding to TACI and BCMA; (3) sBCMA inhibits APRIL and AGP3 binding to its receptors; (4) sBCMA ameliorates T cell dependent and T cell independent humoral immune responses in vivo; (5) sTACI inhibits APRIL and AGP3 binding to its receptors and ameliorates T cell dependent and T cell independent humoral immune responses in vivo; and (6) BCMA exhibits similarity with TACI within a single cysteine rich domain located N-terminal to a potential transmembrane domain. These discoveries provides a strategy for development of therapeutics for treatment of autoimmune diseases, and cancer, for prevention of transplant rejection. Disease states and disease parameters associated with APRIL and AGP-3 may be affected by modulation of BCMA or TACI; disease states and parameters associated with TACI can be affected by modulation of APRIL; disease states and parameters can be affected by modulation of any of TACI, BCMA, APRIL and AGP-3 by a single therapeutic agent or two or more therapeutic agents together.

Nucleic Acids Encoding Mk61 Receptors

View page
US Patent:
7153669, Dec 26, 2006
Filed:
Sep 5, 2001
Appl. No.:
09/948018
Inventors:
Lars Eyde Theill - Thousand Oaks CA, US
Richard Yeh - Ithaca NY, US
Scott Michael Silbiger - Woodland Hills CA, US
Gang Yu - Thousand Oaks CA, US
Giorgio Senaldi - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C12N 15/12
C12N 15/62
US Classification:
435 691, 436 697, 4363201, 43625411, 436325, 43625233, 436 6, 536 234, 536 235, 530350, 5303873
Abstract:
Novel MK61 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing MK61 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with MK61 polypeptides.

Antibody To Tnf Receptor-Like Molecules

View page
US Patent:
7569387, Aug 4, 2009
Filed:
May 17, 2006
Appl. No.:
11/436207
Inventors:
Lars Eyde Theill - Thousand Oaks CA, US
Richard Yeh - Ithaca NY, US
Scott Michael Silbiger - Woodland Hills CA, US
Gang Yu - Thousand Oaks CA, US
Giorgio Senaldi - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C07K 16/28
C12N 5/16
US Classification:
435334, 53038822, 5303881, 53038815, 5303871, 5303915, 5303911
Abstract:
Novel MK61 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing MK61 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with MK61 polypeptides.

Dkr Polypeptides

View page
US Patent:
7723478, May 25, 2010
Filed:
Aug 14, 2007
Appl. No.:
11/893211
Inventors:
Michael Brian Bass - Thousand Oaks CA, US
John Kevin Sullivan - Newbury Park CA, US
Lars Eyde Theill - Thousand Oaks CA, US
Daguang Wang - New York NY, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C07K 14/00
US Classification:
530350
Abstract:
Disclosed are nucleic acid molecules encoding novel DKR polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

Methods And Compositions Of Matter Concerning April/G70, Bcma, Blys/Agp-3, And Taci

View page
US Patent:
20020086018, Jul 4, 2002
Filed:
May 14, 2001
Appl. No.:
09/855158
Inventors:
Lars Theill - Thousand Oaks CA, US
Gang Yu - Thousand Oaks CA, US
International Classification:
A61K039/395
US Classification:
424/146100, 424/153100
Abstract:
This invention concerns interactions among APRIL/G70, AGP-3/BLYS, BCMA, and TACI and related methods of use and compositions of matter. It has been found that (1) sAPRIL/G70 binds to the cell-surface receptors BCMA and TACI on T and B lymphoma cells, resulting in stimulation of proliferation of primary human and mouse B and T cells both in vitro and in vivo; (2) APRIL competes with AGP3's binding to TACI and BCMA; (3) sBCMA inhibits APRIL and AGP3 binding to its receptors; (4) sBCMA ameliorates T cell dependent and T cell independent humoral immune responses in vivo; (5) sTACI inhibits APRIL and AGP3 binding to its receptors and ameliorates T cell dependent and T cell independent humoral immune responses in vivo; and (6) BCMA exhibits similarity with TACI within a single cysteine rich domain located N-terminal to a potential transmembrane domain. These discoveries provides a strategy for development of therapeutics for treatment of autoimmune diseases, and cancer, for prevention of transplant rejection. Disease states and disease parameters associated with APRIL and AGP-3 may be affected by modulation of BCMA or TACI; disease states and parameters associated with TACI can be affected by modulation of APRIL; disease states and parameters can be affected by modulation of any of TACI, BCMA, APRIL and AGP-3 by a single therapeutic agent or two or more therapeutic agents together.

Novel Dkr Polypeptides

View page
US Patent:
20020161178, Oct 31, 2002
Filed:
Oct 9, 2001
Appl. No.:
09/976736
Inventors:
Michael Bass - Thousand Oaks CA, US
John Sullivan - Newbury Park CA, US
Lars Theill - Thousand Oaks CA, US
Daguang Wang - Thousand Oaks CA, US
Assignee:
Amgen Inc.
International Classification:
C07H021/02
C07H021/04
A61K031/70
A01N043/04
C12P019/34
C12N007/00
C12N007/01
C12N007/02
C07K002/00
C07K004/00
C07K005/00
C07K007/00
C07K014/00
C07K016/00
C07K017/00
A61K038/00
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74
C12N005/06
C12N005/16
G01N033/53
US Classification:
530/324000, 530/300000, 435/091100, 435/320100, 435/235100, 435/239000, 435/345000, 436/548000, 514/044000, 536/023100
Abstract:
Disclosed are nucleic acid molecules encoding novel DKR polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

Novel Dkr Polypeptides

View page
US Patent:
20050153330, Jul 14, 2005
Filed:
Nov 24, 2004
Appl. No.:
10/998271
Inventors:
Michael Bass - Thousand Oaks CA, US
John Sullivan - Newbury Park CA, US
Lars Theill - Thousand Oaks CA, US
Daguang Wang - Thousand Oaks CA, US
International Classification:
C12Q001/68
C07H021/04
C07K014/705
US Classification:
435006000, 435069100, 435320100, 435325000, 530350000, 536023500
Abstract:
Disclosed are nucleic acid molecules encoding novel DKR polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
Control profile
Lars Eyde Theill from Thousand Oaks, CA, age ~68 Get Report